American Medical Association statement on antibody treatments

Community NewsNews
295

Translate to Spanish or other 102 languages!

We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.
We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Gerald E. Harmon, M.D.
President, American Medical Association

“Given the latest data showing the Omicron variant of SARS-CoV-2 is responsible for 99% of current COVID-19 infections, we are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Limiting the use of these treatments will help ensure patients receive the best available therapy. We encourage physicians to reference the current National Institutes of Health (NIH) COVID-19 treatment guidelines for the latest information on authorized therapies and recommendations for their use.

“We continue to strongly urge every eligible individual to make sure they are up to date on their COVID-19 vaccinations, including booster doses. The Omicron variant is highly contagious and the unvaccinated remain most at risk of severe illness, hospitalization and death if infected. Data further suggests that a booster dose provides greater protection against the Omicron variant.”

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
What drives vaccine hesitancy?
Next article
Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune System

More Articles

What You Need to Know About Aortic Dissection

An aortic dissection – a tear in the inner layer of the main artery – is a life-threatening emergency. It can happen with little warning, as apparently was the case with U.S. Sen. Lindsey Graham. His sudden death at age 71 was preliminarily attributed to an aortic dissection stemming from plaque buildup in his arteries.

DHR Health’s Free Seminar on Breakthrough Treatment for Stroke Survivors, Sept. 19th

DHR Health’s Neuroscience Institute will host a free seminar for stroke survivors who want improved hand and arm movement as many stroke survivors experience impaired mobility and loss of function in the arm which can significantly affect their ability to   perform everyday activities.

DHR Health Transplant Institute Bringing New Era to South Texas

Something significant is happening in medicine in the Rio Grande Valley. A level of specialized care that once routinely required Valley patients to travel hundreds of miles is now being delivered close to home — and earning recognition among leading kidney transplant programs in Texas and across the nation. DHR Health Transplant Institute has reached No. 2 in Texas and No. 16 nationally, marking an important moment for advanced medicine in South Texas.

DHR Health Transplant Success Signals a New Era for Advanced Medicine in the Rio Grande Valley

The significance of DHR Health Transplant Institute’s latest recognition extends far beyond a hospital ranking. It raises a larger question for South Texas: Has the Rio Grande Valley reached the point where patients can look to the region not only for local healthcare, but for nationally competitive transplant medicine?
- Advertisement -